A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.
about
Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation.(±)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice.BH3 mimetic-elicited Ca2+ signals in pancreatic acinar cells are dependent on Bax and can be reduced by Ca2+-like peptides.
P2860
A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A phase II trial of the BCL-2 ...... tastatic head and neck cancer.
@en
A phase II trial of the BCL-2 ...... tastatic head and neck cancer.
@nl
type
label
A phase II trial of the BCL-2 ...... tastatic head and neck cancer.
@en
A phase II trial of the BCL-2 ...... tastatic head and neck cancer.
@nl
prefLabel
A phase II trial of the BCL-2 ...... tastatic head and neck cancer.
@en
A phase II trial of the BCL-2 ...... tastatic head and neck cancer.
@nl
P2093
P2860
P50
P1476
A phase II trial of the BCL-2 ...... etastatic head and neck cancer
@en
P2093
Ammar Sukari
Andrew Shuman
Assuntina G Sacco
Avraham Eisbruch
Carol Bradford
Emily Bellile
Erin McKean
Francis P Worden
Gregory T Wolf
Jacques E Nör
P2860
P2888
P304
P356
10.1007/S10637-016-0364-5
P577
2016-05-26T00:00:00Z